ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

radiprodil

Also written as “Radiprodil”, “RGH-896” and “Radiprodil with Carbamazepine”.

Its studies are mostly in Tuberous Sclerosis · Neurodevelopmental Disorders · Spasms, Infantile · Pain, led by 3 companies.

Drug pageRadiprodil: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 31, 202510 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GRIN Therapeutics75 open or runningphase 3since Oct 31, 2025Feb 22, 2023Nov 2026phase 1 · NCT05818943
UCBits history only20 open or runningphase 2since Jul 8, 2016Jan 4, 2016none ahead
AbbVieits history only10 open or runningphase 2since Feb 5, 2009Feb 5, 2009none ahead

Also a collaborator on its studies: Angelini Pharma, Avance Clinical Pty, PRA Health Sciences and Gedeon Richter.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GRIN Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 22, 2023First study: phase 1 study in GRIN-related DisordersFirst studyNCT05818943 · 24 enrolled · United States, Australia, Canada and more
  2. Apr 23, 2024Phase 2 study in Tuberous SclerosisNCT06392009 · 30 enrolled · Australia, Belgium, Canada and more
  3. Apr 11, 20252 phase 1 studies in Tuberous SclerosisNCT06975605, NCT06965881
  4. Oct 31, 2025Phase 3 study in GRIN-related Neurodevelopmental DisorderNCT07224581 · 100 planned · United States, Australia, Belgium and more
  5. Feb 26, 2026Phase 1 study in Hepatic ImpairmentNCT07457229 · 40 planned · United States
  6. Nov 5, 2026Phase 1 study in GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-FunctionNCT07941206 · 27 planned

Ahead

  1. Nov 2026Primary completion: phase 1 study in GRIN-related DisordersNCT05818943
  2. May 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07457229
  3. May 2027Primary completion: phase 3 study in GRIN-related Neurodevelopmental DisorderNCT07224581
  4. Oct 2027Primary completion: phase 1 study in GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-FunctionNCT07941206

TargetBeta

“Glutamate NMDA receptor; GRIN1/GRIN2B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsketamineruleJohnson & Johnsonphase 451
MemantineruleAbbViephase 429

Studies

All 7 GRIN Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07941206GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function1Not yet recruitingOct 202727
NCT07457229Hepatic Impairment · United States1RecruitingMay 202740
NCT07224581GRIN-related Neurodevelopmental Disorder · United States, Australia, Belgium and more3RecruitingMay 2027100
NCT06975605Tuberous Sclerosis · Australia1CompletedJul 10, 202518
NCT06965881Tuberous Sclerosis · Australia1TerminatedJul 8, 202530
NCT06392009Tuberous Sclerosis · Australia, Belgium, Canada and more2Active, not recruitingJun 202630
NCT05818943GRIN-related Disorders · United States, Australia, Canada and more1Active, not recruitingNov 202624

How it is read

Names in the registry

  • “Radiprodil”, 6 entries
  • “RGH-896”, 3 entries
  • “Radiprodil with Carbamazepine”, 1 entry
  • “Radiprodil with Itraconazole”, 1 entry
  • “Radiprodil + co-administered drugs”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.